ArticleJournal of vascular surgery cases and innovative techniques2026
Percutaneous management of post-thrombotic syndrome: Early experience with a novel thrombectomy catheter designed to address chronic venous occlusions.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-thrombotic syndrome (PTS) is a chronic sequela of deep vein thrombosis, often associated with significant morbidity and limited treatment options in advanced cases. The VenaCore thrombectomy catheter (Inari Medical, Irvine California) has been developed to address chronic venous occlusions without the need for stenting. Methods: This retrospective single-center review examined the first eight consecutive patients with PTS treated with the VenaCore catheter at our institution between September and December 2024. Clinical data, procedural details, technical success, safety outcomes, and 30-day follow-up imaging and symptom assessment (Villalta score) were evaluated. A comprehensive description of our endovascular approach and device technique is provided. Results: Eight patients (4 female, 4 male; median age 39 years) were treated. The median time since deep vein thrombosis diagnosis was 2 years (range, 6 months to 20 years). All patients had moderate to severe PTS symptoms. Technical success was achieved in seven of the eight patients (88%). The median length of occlusion crossed was 20 cm. A mix of both iliofemoral and femoropopliteal occlusions were treated (4:4). The median VenaCore device time was 10 minutes, with luminal gain observed in all cases. One vessel rupture was encountered (managed successfully). At the 30-day follow-up, treated segments remained patent in six of the seven successfully recanalized patients (86%). Improvement in symptoms was reported by these six patients, with a mean reduction in Villalta score of 4.8 (interquartile range, 4.0-5.0) observed. Conclusions: In our initial experience, the VenaCore thrombectomy catheter demonstrated promising technical performance in improving luminal gain and symptom relief in patients with PTS, with an acceptable safety profile. Further studies are warranted to assess long-term patency and clinical durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.